SMC
Loading...
Data returned from the Piano 'meterActive/meterExpired' callback event.
As a subscriber, you are shown 80% less display advertising when reading our articles.
Those ads you do see are predominantly from local businesses promoting local services.
These adverts enable local businesses to get in front of their target audience – the local community.
It is important that we continue to promote these adverts as our local businesses need as much support as possible during these challenging times.
First treatment for 'potentially life-threatening' heart condition approved for use
The Scottish Medicines Consortium (SMC) has approved Tafamidis for the treatment of a rare heart condition called amyloidosis cardiomyopathy (ATTR-CM).
'So happy': Joy for Glasgow woman accepted to study medicine on fourth attempt